Intervention Review

Pharmacologic treatment of depression in multiple sclerosis

  1. Marcus W Koch1,*,
  2. Arjon Glazenborg2,
  3. Maarten Uyttenboogaart3,
  4. Jop Mostert4,
  5. Jacques De Keyser5

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 16 FEB 2011

Assessed as up-to-date: 8 DEC 2010

DOI: 10.1002/14651858.CD007295.pub2

How to Cite

Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD007295. DOI: 10.1002/14651858.CD007295.pub2.

Author Information

  1. 1

    Faculty of Medicine, University of Calgary, Department of Clinical Neurosciences, Calgary, Alberta, Canada

  2. 2

    Mental Health Care Centre Drenthe, Emmen, Netherlands

  3. 3

    University Medical Center Groningen, Department of Neurology, Groningen, Netherlands

  4. 4

    Rijnstate Hospital Arnhem, Department of Neurology, Arnhem, Netherlands

  5. 5

    Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Department of Neurology, Brussels, Belgium

*Marcus W Koch, Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Foothills Hospital, 1403 - 29 Street NW, Calgary, Alberta, T2N 2T9, Canada.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 16 FEB 2011


Cited in:


This article has been cited by:

  1. 1
    S. Askey-Jones, A.S. David, E. Silber, P. Shaw, T. Chalder, Cognitive behaviour therapy for common mental disorders in people with Multiple Sclerosis: A bench marking study, Behaviour Research and Therapy, 2013, 51, 10, 648


  2. 2
    David Myland Kaufman, Mark J. Milstein, Kaufman's Clinical Neurology for Psychiatrists, 2013,